Latest Updates
-
Amitabh Bachchan's Misunderstood Blog Sparked Concern, But His Real Medical Battles Define Resilience -
Jaipur Ranks 6th Among World's Happiest Cities 2026: The Culture Behind The Joy -
Why Green Is the Colour of Sawan: History, Symbolism, and Styling Tips -
Legionnaires' Disease Outbreak: What It Is, Symptoms, Causes, And Prevention Explained -
Ananya Panday's Gaurav Gupta Couture Featured 12,000 Pearls, 2,600 Petals And A Celestial Love Story -
Kharchi Puja 2026: Tripura's Ancient Festival Where The Heads Of Fourteen Deities Are Worshipped -
World Brain Day 2026: How Quality Sleep Helps Safeguard Your Brain Health -
National Mango Day 2026: Why Mango Is Called The 'King Of Fruits' And What Sets It Apart -
Is It Monsoon Hair Fall Or Something More Serious? How To Tell -
World Brain Day 2026: Date, History, Theme, and Why It Matters
NTAGI Recommends Vaccination Against Cervical Cancer And Typhoid: Sources
The government advisory panel NTAGI on Tuesday is learnt to have recommended vaccination against cervical cancer and typhoid after examining the data in this regard. The separately constituted HPV working group of NTAGI had on June 8 reviewed the clinical trial data and the usefulness of Serum Institute's indigenously-developed and India's first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer for inclusion in the National Immunization program, sources said.

According to official sources, the subject expert committee of Central Drugs Standard Control Organisation (CDSCO) had on June 15 recommended granting market authorisation to the qHPV jab. The approval of the Drugs Controller General of India (DCGI) in the matter is still awaited.
Prakash Kumar Singh, director, government and regulatory affairs at Serum Institute of India (SII) had applied to DCGI seeking market authorisation of qHPV after the phase 2/3 clinical trial was completed with the support of the Department of Biotechnology to ensure its early availability in the country, sources said.
According to the application submitted to DCGI by Singh, qHPV vaccine CERVAVAC has demonstrated robust antibody response that is nearly 1,000 times higher than the baseline against all targeted HPV types and in all dose and age groups.
The application mentioned that lakhs of women are diagnosed every year with cervical cancer as well as few other cancers and the death ratio is also very high.
Cervical cancer in India ranks as the second most frequent cancer among women between 15 and 44 years of age.
Also, it is noteworthy that presently India is fully dependent on foreign manufacturers for the HPV vaccine.
Typhoid is a bacterial infection that can lead to high fever, diarrhoea and vomiting. It is caused by the bacterium Salmonella typhimurium (S. typhi). If not detected and treated early, it can be fatal.
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.



Click it and Unblock the Notifications